Singapore markets closed
  • Straits Times Index

    +2.80 (+0.11%)
  • S&P 500

    -7.56 (-0.22%)
  • Dow

    -97.97 (-0.35%)
  • Nasdaq

    -31.80 (-0.28%)

    +1,828.57 (+16.54%)
  • CMC Crypto 200

    +13.50 (+5.51%)
  • FTSE 100

    -25.69 (-0.44%)
  • Gold

    -10.10 (-0.52%)
  • Crude Oil

    +0.14 (+0.35%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Nikkei

    -165.19 (-0.70%)
  • Hang Seng

    +31.71 (+0.13%)
  • FTSE Bursa Malaysia

    +6.40 (+0.43%)
  • Jakarta Composite Index

    -4.63 (-0.09%)
  • PSE Index

    +66.04 (+1.05%)

Covidien's Two Neurovascular Trial Enrolments on Track

Zacks Equity Research

Covidien plc (COV) has started enrolling patients for two clinical trials designed to highlight the safety and effectiveness of its advanced neurovascular solutions. The PREMIER Prospective study is designed to evaluate Covidien’s Pipeline embolization device while the STRATIS Registry for Endovascular Stroke Devices will evaluate all its market-released stroke devices.

The PREMIER Prospective Study

The PREMIER study is an international Investigational Device Exemption clinical study which will assess the safety and efficacy of Covidien’s Pipeline device in the treatment of unruptured, small and medium wide-necked intracranial aneurysms.

The first patient enrolled in the PREMIER study was treated at Baptist Medical Center in Jacksonville, FL. The study will eventually register up to 141 patients at 20 global sites in an effort to provide valuable clinical evidence in a new population of aneurysms.

The STRATIS Registry

The STRATIS Registry is a prospective, multi-center, non-randomized, observational registry intended to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with acute ischemic stroke. Notably, Covidien’s current endovascular stroke device in the U.S. is the Solitaire 2 revascularization device.

Baptist Health Lexington in Kentucky enrolled the first patient in the STRATIS Registry. Going forward, as many as 60 U.S. sites are expected to participate in the STRATIS Registry, which will enroll up to 1,000 patients to collect clinical outcomes for interventional stroke patients in a real world setting.

Going Forward

Covidien continues to design outcome-based clinical studies to confirm the real world safety and efficiency of its highly-developed neurovascular technologies. It intends to explore new applications for unmet medical needs.

Currently, Covidien carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical products industry include ICU Medical (ICUI), Abaxis, Inc. (ABAX) and Eagle Pharmaceuticals (EGRX). ICU Medical sports a Zacks Rank #1 (Strong Buy), while both Abaxis and Eagle Pharmaceuticals carry a Zacks Rank #2 (Buy).

Read the Full Research Report on COV
Read the Full Research Report on ABAX
Read the Full Research Report on ICUI
Read the Full Research Report on EGRX

Zacks Investment Research